Shots:
- The companies collaborated to initiate a P-III trial to evaluate the safety & efficacy of INO-4800 (2.0mg, two-dose regimen, given at a gap of 1 mos.) in healthy men & non-pregnant women aged ≥18yrs. with COVID 19 across Latin American & Asia. The study expected to commence in summer across the globe
- The 1EPs of the trial will be virologically confirmed COVID-19 disease. The P-II data showed that the therapy was well-tolerated & immunogenic in all tested age groups
- Under the expanded collaboration, Advaccine get rights to additional Asian countries outside of Greater China
Click here to read full press release/ article | Ref: PR Newswire | Image: Inovio
The post Inovio Expands its Partnership with Advaccine to Initiate P-III Efficacy Trial for INO-4800 to Treat COVID-19 first appeared on PharmaShots.
